Sangamo Biosciences ( (SGMO) ) has released its Q3 earnings. Here is a breakdown of the information Sangamo Biosciences presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sangamo Therapeutics is a genomic medicine company focused on developing treatments for serious neurological diseases through innovative technologies like zinc finger epigenetic regulators and proprietary capsid discovery platforms. The company recently reported its third-quarter 2025 financial results, highlighting significant progress in its clinical and pre-clinical pipeline, including advancements in Fabry disease and chronic neuropathic pain studies.
In the latest earnings report, Sangamo Therapeutics shared promising clinical data from its STAAR study on Fabry disease, showcasing the potential of isaralgagene civaparvovec as a durable, one-time treatment. The company also announced the commencement of patient recruitment for its Phase 1/2 STAND study targeting chronic neuropathic pain, marking a milestone in its neurology clinical research.
Key financial metrics revealed a net loss of $34.9 million for the third quarter of 2025, a significant shift from a net income of $10.7 million in the same period in 2024. This change was primarily due to a substantial decrease in revenues, attributed to the absence of collaboration-related income from Genentech, which was recorded in the previous year. Operating expenses saw a slight reduction, reflecting Sangamo’s strategic focus on lean operations and advancing its Fabry disease program.
Despite the financial challenges, Sangamo remains optimistic about its future, with plans to submit a Biologics License Application for its Fabry disease treatment by early 2026. The company continues to seek partnerships for commercialization and remains committed to advancing its innovative therapies in the neurology sector.
Looking ahead, Sangamo Therapeutics is poised to continue its strategic focus on developing groundbreaking genomic therapies, with a keen eye on regulatory submissions and potential collaborations to enhance its market presence and financial stability.